Accordingly, we found that Abl suppression via genetic (RNAi or knock-out) or pharmacological (Imatinib) treatments, also has beneficial effects in C. elegans AD models and provided evidence that Imatinib works through Abl also in C. elegans, as its effect is masked in the abl-1 knock-out strain. Here, ABL1 is linked to Alzheimer disease.